Bolt Biotherapeutics, Inc.
NASDAQ:BOLT
Overview | Financials
Company Name | Bolt Biotherapeutics, Inc. |
Symbol | BOLT |
Currency | USD |
Price | 0.588 |
Market Cap | 22,512,179 |
Dividend Yield | 0% |
52-week-range | 0.475 - 1.56 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Randall C. Schatzman Ph.D. |
Website | https://www.boltbio.com |
An error occurred while fetching data.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD